A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple Sclerosis
Uno studio multicentrico di fase 1 del trapianto di cellule ematopoietiche allogeniche per la sclerosi multipla progressiva primaria mediante ORCA-Q, un innesto donatore ingegnerizzato derivato da sangue periferico mobilizzato
A study of allogeneic hematopoietic cell transplantation (alloHCT) with Orca-Q for the treatment of primary progressive multiple sclerosis (PPMS).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study will evaluate alloHCT with Orca-Q, an allogeneic hematopoietic graft isolated from a donor's hematopoietic cells for the treatment of PPMS.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: James S. McClellan, MD, PhD
- Numero di telefono: 650-246-9601
- Email: info@orcabio.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria (Recipient):
-
Participants aged ≥18 and ≤65 years with PPMS
a. A diagnosis of PPMS by 2024 McDonald criteria and 2013 clinical course revision
-
Cerebrospinal fluid (CSF) with elevated IgG index or 2 or more oligoclonal bands
-
EDSS between 2.0 and 5.5 inclusive
-
Based on review of the clinical records, there must be a deterioration in the EDSS of at least 1 or more points over the previous 4 years (or less)
-
Eligibility criteria confirmed by the Eligibility Review Group
-
Recipients who have been treated with ocrelizumab, rituximab, ofatumumab, ublituximab, or alemtuzumab must undergo a washout period as specified in the protocol prior to their planned day 0
-
Recipients must be willing to undergo mobilized autologous peripheral blood stem cell collection to create a cryopreserved rescue product prior to alloHCT
-
Willing to undergo MAC preparative regimen
-
Matched to either a related or unrelated donor as follows:
- Matched related donor who is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
- Matched unrelated donor who is a 10/10 match at HLA-A, -B, -C, -DRB1 and -DQB1, all typed using DNA-based high-resolution methods
-
Negative serum or urine β-HCG test in persons of childbearing potential
Exclusion Criteria:
-
History of Progressive Multifocal Leukoencephalopathy
-
Organ dysfunction or disease that would jeopardize survival after hematopoietic cell transplantation, including but not limited to the following:
- Renal insufficiency as defined by an estimated GFR <60 mL/minute
- Cardiac dysfunction as defined by symptomatic coronary artery disease, congestive heart failure, valvular heart disease, cardiomyopathy, uncontrolled arrhythmia(s), or left ventricular ejection fraction <50%. Participants with a history of these conditions may enroll if they are demonstrated to have optimal cardiac function (as defined by echocardiography or multi-gated acquisition scan)
- Pulmonary dysfunction that poses a risk of mortality after transplant, defined as pre-transplant pulmonary function testing demonstrating a FEV1 <70% expected and/or a DLCOadj <70% expected
- Necroinflammatory or fibrotic liver disease with evidence of liver dysfunction, including but not limited to jaundice, hepatic encephalopathy, or portal hypertension
- Marrow dysfunction that poses a risk of peri-transplant mortality, defined as an absolute neutrophil count (<1000/mm3) below the lower limit of normal, or a platelet count below 50,000/mm3
- Poorly controlled hypertension despite appropriate therapy, defined as a diastolic blood pressure greater than 90 mm Hg while on therapy
- Poorly controlled diabetes mellitus, defined as HgbA1c ≥ 6.5% despite therapy or recurrent hypoglycemia while on therapy
- Extreme protein-calorie malnutrition defined by Body Mass Index <18 and unintentional weight loss (3 kg in the last month or 6 kg in the last 6 months.)
-
History of smoking either tobacco or other herbal products in the last 3 months
-
Planned pharmaceutical in vivo or ex vivo T cell depletion (TCD), (eg, cladribine, or peritransplant antithymocyte globulin [ATG]). For participants who have previously been exposed to a TCD agent, a 5-half-life washout of the agent must occur prior to planned day 0 (day 0 is defined as the day of Orca-Q infusion). The washout period for alemtuzumab is specified in the protocol
-
HIV seropositive
-
HBV serology results indicating chronic HBV infection per https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm, unless HBV PCR negative. HBV seropositive participants should be on antiviral therapy after transplant
-
HCV seropositive, unless PCR negative and having undergone 'curative' antiviral therapy
-
Participant has active uncontrolled infection
-
Participant has demonstrated lack of compliance with prior medical care
-
Participants with known active malignancy. It is recommended that patients are current on cancer screening tests for their age and family history as per the NCCN [The National Comprehensive Cancer Network®] Guidelines. Screening should be performed, if indicated, per NCCN guidelines prior to study treatment.
-
Participants whose life expectancy is severely limited by illness other than multiple sclerosis
-
Females who are pregnant or breast feeding
-
Medical or psychiatric conditions that compromise ability to give informed consent or to comply with treatment protocol
-
Inability to undergo an MRI scan
-
Currently receiving treatment with investigational agents
-
Positive for JC virus DNA in the CSF or blood during screening
-
Known allergy or hypersensitivity to or intolerance of tacrolimus
-
Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal, or Streptomyces avidinii proteins
-
Recipient-positive antidonor HLA antibodies against a mismatched allele in the selected donor determined by either of the following:
- Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, or HLA-DPA1
- Presence of antidonor HLA antibody to any of the following HLA loci (if mismatched): HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1, or HLA-DPB1, with mean fluorescence intensity ≥1000 by solid phase immunoassay
-
People of childbearing potential (POCBP) or men who have sexual contact with POCBP who are unwilling to use effective forms of birth control or abstinence for 1 year after transplantation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Orca-Q Graft with myeloablative conditioning regimen
Donor Orca-Q stem cell graft |
Allogeneic (donor) stem cell graft Myeloablative regimen of busulfan, fludarabine, and thiotepa.
Altri nomi:
Graft-versus-host disease (GVHD) prevention |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Severe acute graft-versus-host-disease-free survival
Lasso di tempo: Up to 6 months after infusion
|
Number of participants who are alive without a history of grade ≥3 (severe) acute graft-versus-host disease (aGVHD), graded per Mount Sinai Acute GVHD International Consortium (MAGIC) criteria (range: grades 0-4 with higher number being worse) |
Up to 6 months after infusion
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Event-Free Survival (EFS)
Lasso di tempo: Up to 24 months and at year 5 after Orca-Q infusion
|
Participant is alive and free of PPMS progression. An event is defined as sustained loss of neurological function (Expanded Disability Status Scale [EDSS, range of 0-10 with higher numbers being worse] increase >1 point sustained for 3 months), relapse, one or more new or enlarging MRI lesions, or death |
Up to 24 months and at year 5 after Orca-Q infusion
|
|
Loss of Neurological Function or Relapse
Lasso di tempo: Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
Assessment of sustained neurological worsening as measured by EDSS (>1-point increase) or occurrence of PPMS relapse. EDSS spans the range of 0-10 with higher numbers being worse |
Every 3 months through Month 12 and every 6 months from Months 13-24 after transplant
|
|
Overall Survival (OS)
Lasso di tempo: From transplant through 5 years after transplant
|
Time in years from transplant to death from any cause |
From transplant through 5 years after transplant
|
|
Treatment-Related Mortality (TRM)
Lasso di tempo: From start of alloHCT through 5 years after transplant
|
Death definitely or probably resulting from study treatment and not attributable to other causes, as determined by review of clinical and autopsy data |
From start of alloHCT through 5 years after transplant
|
|
Incidence of Disease-Modifying Therapy Use for PPMS After Orca-Q
Lasso di tempo: From Orca-Q infusion through 5 years after transplant
|
Number of participants with initiation or re-initiation of disease-modifying therapy for PPMS following Orca-Q infusion. Use of therapies for GVHD or other transplant-related conditions is excluded |
From Orca-Q infusion through 5 years after transplant
|
|
Incidence of aGVHD
Lasso di tempo: From transplant through 5 years after transplant
|
Number of participants with aGVHD |
From transplant through 5 years after transplant
|
|
Severity of aGVHD
Lasso di tempo: From transplant through 5 years after transplant
|
Severity is graded per MAGIC criteria |
From transplant through 5 years after transplant
|
|
Incidence chronic graft-versus-host disease (cGVHD)
Lasso di tempo: From transplant through 5 years after transplant
|
Number of participants with cGVHD |
From transplant through 5 years after transplant
|
|
Severity of cGVHD
Lasso di tempo: From transplant through 5 years after transplant
|
cGVHD severity will be categorized using NIH global severity scores of mild, moderate, and severe cGVHD |
From transplant through 5 years after transplant
|
|
Incidence of Primary Graft Failure
Lasso di tempo: Through day +28
|
Number of participants alive without recovery of neutrophils [ie, without achieving an abosolute neutrophil count (ANC) ≥500/mm3 for 3 consecutive days] at day +28 without another identifiable cause |
Through day +28
|
|
Incidence of Secondary Graft Failure
Lasso di tempo: Through day +100
|
Number of participants with neutrophil engraftment followed by subsequent decline in ANC <500/mm3, unresponsive to growth factor therapy, by day +100 without another identifiable cause |
Through day +100
|
|
Time to Neutrophil Engraftment
Lasso di tempo: From transplant through Day +365
|
Neutrophil engraftment is defined as an absolute neutrophil count (ANC) of 500 or more neutrophils per μL blood, sustained for 3 days in a row. The day of neutrophil engraftment is defined as the first day of ANC ≥ 500/μL. Time to neutrophil engraftment is measured in days. |
From transplant through Day +365
|
|
Development of Infectious Complications
Lasso di tempo: From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
Incidence of definite and probable viral, fungal, and bacterial infections occurring after transplantation |
From transplant through Day +730 (2 years), with long-term follow-up through 5 years
|
|
Regimen-Related Toxicity
Lasso di tempo: From start of conditioning through 1 year after transplant
|
Number of participants with regimen-related toxicities (adverse events attributed to the conditioning regimen, Orca-Q, or GVHD prophylaxis), graded per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0 (range: Grade 1-5, with higher grades being worse). |
From start of conditioning through 1 year after transplant
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Processi patologici
- Malattia cronica
- Attributi della malattia
- Malattie autoimmuni
- Malattie del sistema immunitario
- Malattie autoimmuni demielinizzanti, SNC
- Malattie autoimmuni del sistema nervoso
- Malattie demielinizzanti
- Condizioni patologiche, segni e sintomi
- Sclerosi multipla
- Sclerosi Multipla Cronica Progressiva
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Idrocarburi, aciclici
- Idrocarburi
- Alcani
- Alcoli
- Glicoli butilene
- Glicoli
- Mesilati
- Alcanesolfonati
- Acidi alcanesolfonici
- Acidi solfonici
- Acidi zolfo
- Macrolidi
- Lattoni
- Fosforamidi
- Composti organofosfori
- Trietilenefosforamide
- Aziridine
- Azirines
- Tacrolimo
- Busulfan
- Tiotepa
- fludarabina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- OQ PPMS
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .